Scarica l'app Stockscreener
7.65
1.67%
-0.13
Dopo l'orario di chiusura:
7.65
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst Pharmaceuticals Q3FY26 Results: Earnings call set for Nov 4 - scanx.trade
BioCryst to Report Third Quarter 2026 Financial Results on November 4 - The Manila Times
BioCryst to Report Third Quarter 2026 Financial Results on November 4 - GlobeNewswire
A live webcast will accompany BioCryst’s results call at 8:30 a.m. ET on Nov. 4. - Stock Titan
BioCryst Pharmaceuticals (BCRX) Gains FDA Nod for New Orladeyo O - GuruFocus
BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ) - Seeking Alpha
BioCryst wins FDA approval for ORLADEYO pellet formulation - Investing.com
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE - GlobeNewswire Inc.
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE - Yahoo Finance
Wedbush Cuts Price Target on BioCryst Pharmaceuticals to $18 From $20, Keeps Outperform Rating - Yahoo Finance
BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble? - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders - BioBuzz
BioCryst Pharmaceuticals stock fell 1.85 percent on October 6 - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board - AD HOC NEWS
BioCryst Pharmaceuticals Inc (BO1.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BioCryst Pharmaceuticals stock gets a new science board - AD HOC NEWS
Discipline and Rules-Based Execution in BCRX Response - Stock Traders Daily
Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board - www.marketscreener.com
BioCryst forms scientific advisory board for R&D strategy By Investing.com - Investing.com India
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth - GlobeNewswire
JPMorgan raises target for BioCryst Pharmaceuticals stock - AD HOC NEWS
BioCryst Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by JP Morgan - Moomoo
BCRX Maintained by JP Morgan -- Price Target Raised to $13.00 - GuruFocus
J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 - Moomoo
Claude AI Just Bought These 2 Pharma Stocks - finance.yahoo.com
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Options ChainYahoo Finance - Yahoo! Finance Canada
Is BioCryst’s (BCRX) Newest Approval Bigger Than It Looks? - finance.yahoo.com
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
BioCryst Pharmaceuticals stock gains 0.92 percent as earnings beat estimates - AD HOC NEWS
Biopharma Stock With Layers of Technical Support in Place - Yahoo Finance
Biopharma Stock With Layers of Technical Support in Place - Schaeffer's Investment Research
BioCryst Eyes $1B Rare-Disease Future Through External Innovation - Yahoo Finance
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - AlphaStreet
BioCryst (BCRX) Turns its First Profit and Now Wants to Go Shopping for Rare Disease Drugs - Yahoo Finance
BioCryst Pharmaceuticals (BCRX) Could Be 62% Undervalued On Its ORLADEYO Growth Story - Yahoo Finance
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity (NASDAQ:BCRX) - Seeking Alpha
BCRX Downgraded by RBC Capital -- Price Target Lowered to $11.00 - GuruFocus
RBC Downgrades BioCryst to Sector Perform Amid Competitive Pressures - Intellectia AI
BCRX Looks 24.9% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BioCryst Pharma (BCRX): ORLADEYO Growth And Pipeline Catalysts Shape The Long-Term Outlook - RTTNews
BioCryst's Orladeyo Approved for HAE Attack Prevention - Intellectia AI
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Yahoo Finance
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease - Stocktwits
CareMed Has Been Selected as a National Pharmacy Partner by BioCryst and Adds Orladeyo® (berotralstat) to Growing Rare Disease Portfolio - manilatimes.net
4.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):